Brief: Bionomics Initiates Phase 2 Study Of BNC210 For Acute Treatment Of Social Anxiety Disorder
03/01/2022 11:19
Jan 3 (Reuters) - Bionomics Ltd BNO.AX :
* BIONOMICS INITIATES PHASE 2 PREVAIL STUDY OF BNC210 FOR
ACUTE
TREATMENT OF SOCIAL ANXIETY DISORDER
Source text for Eikon: ID:nPn1bgNrqa
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors